|  |
| --- |
| November18, 2016  Contact person specialized press Dr. Jürgen Krauter  Vice President Communications Phone +49 6181 59-6847  Fax +49 6181 59-76847  juergen.krauter@evonik.com |
| Contact person specialized press Hannah Rausche  Head of Communications  Health Care  Phone +49 6151 18-3567  Fax +49 6181 59-76847  hannah.rausche@evonik.com |

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11

45128 Essen

Telefone +49 201 177-01

Fax +49 201 177-3475  
Germany

www.evonik.com

**Supervisory Board**

Dr. Ralph Sven Kaufmann, Chairman

Management Board

Dr. Reiner Beste, Chairman

Dr. Hans Josef Ritzert  
Michael Gattermann  
Markus Schäfer

Registered office Essen

Registered court

Essen local court

Commercial registry B 25784

HR no. FN 431387 v

**Evonik launches its new PQQ product PentaQQ™**

# PentaQQ™ is Evonik’s branded PQQ ingredient

# Evonik Health Care expands its portfolio of health ingredients and formulation solutions

Essen (Germany). Evonik just introduced PentaQQ™, its new brand for pyrroloquinoline quinone (PQQ), also known as methoxatin, a molecule found in very small quantities in certain foods such as fermented soybeans and green pepper. Research suggests that PQQ has a beneficial effect on the mitochondria of human cells and is found in nutritional solutions for the protection of cognitive abilities.

“The dietary supplement market is growing. Around the world, people are becoming increasingly health conscious and are willing to do more to ensure their own well-being. They also want to be sure that dietary supplements are safe and effective. This is where Evonik Health Care can help by supplying the market with high quality ingredients and by formulating these ingredients to maximize stability and bioavailability,” states Dr. Ludger Eilers, Head of Evonik Health Care’s Food Segment.

Evonik supports its customers with health ingredients such as PentaQQ™, the REXIVA® amino acid range, and Healthberry® 865, an extract from Scandinavian bilberries and black currants.

Formulation experts at Evonik have also recently developed ‘floating capsules’ – ideal for nutritional supplement ingredients that only achieve maximum effectiveness if retained in the stomach for an extended period. Evonik has combined EUDRAGUARD® control with a gas-generating agent to design capsules that remain buoyant and gradually release the ingredients over a period of up to four hours inside the stomach. This gives the human body more time to absorb the active substances. This innovative floating capsule technology – named EUDRATEC™ GRS – can also be used to ensure effective administration of other polyphenols or green tea extracts.

Dr. Thomas Hermann, Head of Evonik Health Care’s Pharma & Food Ingredients Product Line, explains, “Our intention is to continue to develop our portfolio of nutritional ingredients and formulation technologies to address health conditions which affect growing segments of the population.”

Evonik’s portfolio of health ingredients and formulation solutions will be highlighted at this year’s HI Europe from 29th of November until 1st of December in Frankfurt, at the Evonik booth (H15).

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around   
€4.9 billion in 2015.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.